Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Thorac Oncol. 2020 Apr 27;15(9):1425–1433. doi: 10.1016/j.jtho.2020.04.020

Table 1:

Elements of reporting toxicities and outcome assignments

Reporting element Outcome assignments
What minimum incidence was utilized for reporting toxicities of any grade? 1 patient, 2-3 patients, 5% incidence, 10% incidence, 15-20% incidence, ≥25% incidence, not reported
What minimum incidence was utilized for reporting toxicities grade ≥ 3? 1 patient, 2-3 patients, 5% incidence, 10% incidence, 15-20% incidence, ≥25% incidence, not reported
Were treatment-related toxicities reported? Y/N/Not reported
Were treatment-emergent toxicities reported? Y/N/Not reported
Was a dose-escalation component included? Y/N
Were adverse events combined across dose levels if dose-escalation was included? Y/N
Were dose-limiting toxicities reported if the trial included a dose-escalation component? Y/N
Were key dose-limiting toxicity criteria described? Y/N
Were serious adverse events reported? Y/N
Were key serious adverse event criteria described? Y/N
Were adverse events leading to treatment change reported? Y/N
Were standardized terminology (CTCAE or MedDRA) utilized? Y/N
Were grouped adverse event terms utilized? Y/N
Was overall incidence of adverse events at organ system level reported? Y/N
Was the total number of patients with any adverse event any grade reported? Y/N
Was the total number of patients with any adverse event grade ≥ 3 reported? Y/N